The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed
| Autor: | D. Padmanaban, Gary R. Morrow, Jane T. Hickok, Joseph A. Roscoe, Jennifer J. Griggs, L. J. Gillies |
|---|---|
| Rok vydání: | 2005 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 23:8012-8012 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.8012 |
| Popis: | 8012 Background: Fatigue is the most common adverse effect reported by patients undergoing cancer treatment. Several large studies have shown up to 90% may experience fatigue sometime during treatment. Approximately a quarter report that their fatigue persists for months or even years beyond cancer treatment. Control of this debilitating side effect remains inadequate. Methods: 51 Women (mean age=54.5 yrs) who completed breast cancer treatment an average of 23.5 months previously and who were reporting persistent fatigue were enrolled in a one month open label trial of modafinil (Provigil 200 mg with breakfast). Four patients did not complete the trial: 3 dropped out within a week complaining of ‘agitation’ (all were very slight with weights under 110#), 1 patient found she was unexpectedly pregnant and was withdrawn from the study. All patients completed psychometrically sound measures of fatigue and other side effects before and after treatment. Results: The mean fatigue severity level at baseline for t... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|